Fluoroquinolones for treating tuberculosis

Ziganshina, L. E.; Визель, А. А.; Squire, S. Bertel

doi:10.1002/14651858.cd004795.pub2

Cited by 31 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Trials as first-line agent for drug-sensitive TB resulted in higher relapse rates 10,11 Not recommended Levofloxacin 1.0 More efficacious than ofloxacin for second-line treatment, but ofloxacin resistance may lead to treatment failure 8,12 Recommended for inclusion in MDR-TB regimens Not currently recommended as first-line agent been reported to have a much higher co-resistance to other firstline and second-line agents used in the treatment of TB. 76 …”

Section: Cross-resistance To Newer Fq and Other Second-line Tb Drugsmentioning

confidence: 99%

Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems

Jabeen

Shakoor

Hasan

2015

International Journal of Infectious Diseases

View full text Add to dashboard Cite

Fluoroquinolones (FQ) play an essential role in the treatment and control of multidrug-resistant tuberculosis (MDR-TB). They are also being evaluated as part of newer regimens under development for drug-sensitive TB. As newer FQ-based regimens are explored, knowledge of FQ resistance data from high TB burden countries becomes essential. We examine available FQ resistance data from high TB burden countries and demonstrate the need for comprehensive surveys to evaluate FQ resistance in these countries. The factors driving FQ resistance in such conditions and the cost of such resistance to weak healthcare systems are discussed. The need for a comprehensive policy for addressing the issue of FQ resistance is highlighted.

show abstract

Section: Cross-resistance To Newer Fq and Other Second-line Tb Drugsmentioning

confidence: 99%

Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems

Jabeen

Shakoor

Hasan

2015

International Journal of Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…However, newer FQs such as moxifloxacin may be a reasonable alternative based on results from a single clinical trial [30]. Another later Cochrane meta-analysis was unable to establish the value of the newer FQs in the treatment of TB [31].…”

Section: Tuberculosismentioning

confidence: 99%

“…In their review, they also addressed FQ resistance, which increased in most instances over the years, particularly if the patients had been treated previously with FQs and if the report originated in Asia. In the abovementioned meta-analyses [29,31], the use of FQs as first-line drugs for the therapy of TB is discouraged as they are not superior to conventional therapy.…”

Section: Tuberculosismentioning

confidence: 99%

Quinolones for mycobacterial infections

Rubinstein

Keynan

2013

International Journal of Antimicrobial Agents

View full text Add to dashboard Cite

“…Simultaneously in the 1980s, FQs were discovered and proved useful not only for susceptible TB, but also for resistant strains [29,30]. Invariably, FQ discovery has thus far been the main achievement in MDR-TB treatment [31,32], but the irrational use of these drugs for other infections and among TB patients has aggravated the problem, thus promoting the emergence of XDR-TB.…”

Section: Mdr-tb As a Public Health Problem: The Impact Of Hivmentioning

confidence: 99%

“…At the same time, levofloxacin 1000 mg (double regular dosage) is showing similar efficacy to moxifloxacin with a reduction in total costs [78]. However, the actual role of the new FQs in the initial phase of treatment remains unclear [30,78]. It is necessary to address whether new-generation FQs, such as gatifloxacin and moxifloxacin, could have similar sterilizing activity to RMP.…”

Section: Expert Commentarymentioning

confidence: 99%

MDR-/XDR-TB management: what it was, current standards and what is ahead

Monedero¹,

Caminero²

2009

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Despite killing nearly 2 million people every year, TB is arguably the most neglected disease in terms of the funding and research it receives. In many ways, multidrug-resistant TB is a result of this disregard. In high-burden countries, not many improvements have been implemented in the diagnosis and treatment tools of TB since the 1960s. Following this period, fluoroquinolones, developed for other infections, are the only highly active new drugs against TB. Multidrug- and extensively drug-resistant TB is booming worldwide as a result of insufficient control measures. Furthermore, the prevalence of this disease is substantially facilitated by the HIV epidemic. After a deadly and well-reported extensively drug-resistant TB outbreak occurred in HIV-infected patients in South Africa, the threat of an untreatable TB epidemic is receiving increased attention internationally. Nevertheless, drug-resistant management has lacked research and funding over several decades and we are now faced with many controversial issues and little research-based evidence. There are no clinical trials comparing different treatments, and current management is based on personal experiences and agreement between experts. The major challenge for the next few years is to improve the evidence base in order to develop more rational recommendations that adequately address the current problem and avoid making a bad situation worse.

show abstract

Fluoroquinolones for treating tuberculosis

Cited by 31 publications

References 34 publications

Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems

Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems

Quinolones for mycobacterial infections

MDR-/XDR-TB management: what it was, current standards and what is ahead

Contact Info

Product

Resources

About